
|Videos|December 20, 2022
CheckMate 274: Data Updates in MIBC from GU ASCO, ASCO, and ESMO 2022
Author(s)Terence Friedlander, MD
Terence Friedlander, MD, continues his discussion of the CheckMate 247 trial by highlighting important updates from recent conferences on adjuvant nivolumab therapy in patients with MIBC.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Poll Results Reveal Readers’ Top Abstracts at ASH 2025
2
The Targeted Pulse: FDA Approvals, Trial Updates, and ASH 2025 Previews
3
Odronextamab Plus CHOP Shows Promise in Early Phase 3 Data for Untreated DLBCL
4
Lisaftoclax Monotherapy Achieves Significant Responses and PFS in R/R CLL/SLL
5








































